Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 3;324(17):1781-1782.
doi: 10.1001/jama.2020.18796.

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee

Manish M Patel  1 , Natalie J Thornburg  1 , William B Stubblefield  2 , H Keipp Talbot  3 , Melissa M Coughlin  1 , Leora R Feldstein  1 , Wesley H Self  2
Affiliations

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee

Manish M Patel et al. JAMA. .

Abstract

This study examines the duration of antibody response to SARS-CoV-2 in health care personnel over a 60-day period in Nashville, Tennessee.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Coughlin reported US Patent 7,728,110B2, an isolated human monoclonal antibody that specifically binds to SARS-CoV S protein. No other disclosures were reported.

Figures

Figure.
Figure.. Anti–SARS-CoV-2 Signal-to-Threshold Ratios at Baseline and 60 Days in Health Care Personnel Seropositive at Baseline
SARS-CoV-2 indicates severe acute respiratory syndrome coronavirus 2. The dotted line at y = 1.0 indicates the threshold for seropositivity.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. . Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. Published online July 21, 2020. doi:10.1056/NEJMc2025179 - DOI - PMC - PubMed
    1. Long QX, Tang XJ, Shi QL, et al. . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-1204. doi:10.1038/s41591-020-0965-6 - DOI - PubMed
    1. Stubblefield WB, Talbot HK, Feldstein L, et al. ; Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators . Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for COVID-19 patients—Nashville, Tennessee. Clin Infect Dis. 2020;ciaa936. doi:10.1093/cid/ciaa936 - DOI - PMC - PubMed
    1. Havers FP, Reed C, Lim T, et al. . Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med. Published online July 21, 2020. doi:10.1001/jamainternmed.2020.4130 - DOI - PubMed
    1. Premkumar L, Segovia-Chumbez B, Jadi R, et al. . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413 - DOI - PMC - PubMed

Publication types

Substances